CRIS Current Research Information System

SARACINO, ILARIA MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.706
NA - Nord America 3.316
EU - Europa 2.833
SA - Sud America 221
AF - Africa 137
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 10.215
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.250
IT - Italia 1.196
SG - Singapore 1.032
CN - Cina 985
VN - Vietnam 837
GB - Regno Unito 358
HK - Hong Kong 272
SE - Svezia 252
DE - Germania 245
BR - Brasile 175
FR - Francia 151
IN - India 140
NL - Olanda 132
KR - Corea 127
RU - Federazione Russa 110
IE - Irlanda 97
BD - Bangladesh 68
FI - Finlandia 56
JP - Giappone 52
JO - Giordania 50
UA - Ucraina 49
ZA - Sudafrica 47
CA - Canada 46
BG - Bulgaria 34
CI - Costa d'Avorio 26
ID - Indonesia 26
AT - Austria 24
EE - Estonia 21
CH - Svizzera 19
PH - Filippine 19
SC - Seychelles 17
ES - Italia 16
TH - Thailandia 16
AR - Argentina 15
IQ - Iraq 13
BE - Belgio 11
EC - Ecuador 11
TN - Tunisia 11
TR - Turchia 11
TW - Taiwan 11
GR - Grecia 10
MA - Marocco 10
MX - Messico 10
PK - Pakistan 9
TG - Togo 9
LT - Lituania 8
PL - Polonia 7
SA - Arabia Saudita 7
PT - Portogallo 6
RO - Romania 6
AL - Albania 5
CO - Colombia 5
HR - Croazia 5
CL - Cile 4
EG - Egitto 4
MY - Malesia 4
PE - Perù 4
PY - Paraguay 4
RS - Serbia 4
CZ - Repubblica Ceca 3
DK - Danimarca 3
ET - Etiopia 3
IR - Iran 3
LB - Libano 3
PS - Palestinian Territory 3
VE - Venezuela 3
DO - Repubblica Dominicana 2
DZ - Algeria 2
GH - Ghana 2
IL - Israele 2
KZ - Kazakistan 2
NG - Nigeria 2
NP - Nepal 2
OM - Oman 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
UZ - Uzbekistan 2
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BS - Bahamas 1
GD - Grenada 1
GN - Guinea 1
GT - Guatemala 1
HN - Honduras 1
KE - Kenya 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
MM - Myanmar 1
MT - Malta 1
NI - Nicaragua 1
PA - Panama 1
QA - Qatar 1
RE - Reunion 1
SI - Slovenia 1
SN - Senegal 1
TL - Timor Orientale 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 10.215
Salva come PNG Salva come JPEG
Città #
Singapore 722
Ashburn 371
Hefei 316
Southend 298
Hong Kong 261
Chandler 243
San Jose 220
Ho Chi Minh City 195
Fairfield 193
Santa Clara 177
Hanoi 156
Bologna 150
Seoul 119
Dong Ket 108
Woodbridge 108
Beijing 103
Milan 103
Dublin 97
Princeton 96
Boardman 88
Houston 84
Seattle 82
Wilmington 80
New York 75
Los Angeles 69
Rome 69
Lauterbourg 65
Council Bluffs 64
Ann Arbor 62
Cambridge 61
Amman 50
Tokyo 49
Buffalo 40
Helsinki 37
Turin 36
Sofia 33
Berlin 31
Redmond 31
Westminster 31
Nanjing 30
Tappahannock 30
Padova 29
Bengaluru 28
Parma 27
Abidjan 26
Redondo Beach 24
Da Nang 23
Guangzhou 23
Haiphong 23
Jinan 23
Nuremberg 23
Jacksonville 22
Naples 22
São Paulo 22
Munich 21
Dallas 20
Frankfurt am Main 19
Shanghai 19
Lappeenranta 17
Biên Hòa 16
Florence 16
Jakarta 16
Bari 15
Rimini 15
Yubileyny 15
Amsterdam 14
Atlanta 14
Johannesburg 14
Montreal 14
San Diego 14
Shenyang 14
Chicago 13
Modena 13
Phoenix 13
Verona 13
Zhengzhou 13
Changsha 12
Vienna 12
Des Moines 11
Frattamaggiore 11
Shenzhen 11
Toronto 11
Bern 10
Brussels 10
Hebei 10
Orem 10
Catania 9
Denver 9
Hải Dương 9
Lomé 9
Nanchang 9
Norwalk 9
Quận Bình Thạnh 9
Saint Petersburg 9
San Francisco 9
Curitiba 8
Hangzhou 8
London 8
Moscow 8
Mülheim 8
Totale 6.115
Salva come PNG Salva come JPEG
Nome #
Ruolo dei batteri componenti la flora intestinale nell’eziopatogenesi della colite ulcerosa e del cancro del colon: i Fusobatteri e il Bacteroides fragili enterotossico prendono la scena. 584
Sequenze genomiche dei batteri filamentosi segmentati negli animali da laboratorio. Implicazioni per la ricerca sull’uomo 388
Antifungal Activity of Natural Compounds vs. Candida spp.: A Mixture of Cinnamaldehyde and Eugenol Shows Promising In Vitro Results 311
Change of point mutations in helicobacter pylori rRNA associated with clarithromycin resistance in Italy 270
Accuracy of a new ultra fast rapid urease test to diagnose Helicobacter pylori infection in 1000 consecutive patients 223
Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19 219
Palmitoylethanolamide (PEA) for Prevention of Gastroesophageal Inflammation: Insights from In Vitro Models 213
Clove Essential Oil as a Source of Antitumoral Compounds Capable of Crossing the Blood–Brain Barrier: A Focus on the Effects of β-Caryophyllene and Eugenol in a Glioblastoma Cell Line 205
Antimicrobial Efficacy of Five Probiotic Strains Against Helicobacter Pylori 199
Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg) 194
Nutritional Biomarkers for the Prediction of Response to Anti-TNF-α Therapy in Crohn's Disease: New Tools for New Approaches 187
The Effects of Two Novel Copper-Based Formulations on Helicobacter pylori 182
Antibiotic resistance pattern of Helicobacter pylori strains isolated in Italy during 2010-2016 182
Dietary Habits and Nutrient Deficiencies in a Cohort of European Crohn's Disease Adult Patients 180
Antibiotic resistance and therapy outcome in H. pylori eradication failure patients. 177
Therapy for H. pylori: Current concepts 169
Culture-based Selection Therapy for Patients Who Did Not Respond to Previous Treatment for Helicobacter pylori Infection 168
A comparison among three rapid urease tests to diagnose Helicobacter pylori infection in 375 consecutive dyspeptic 168
Antibiotic resistance and therapy for H. pylori infection in immigrant patients managed in Italy 164
A novel stool PCR test for helicobacter pylori may predict clarithromycin resistance and eradication of infection at a high rate 161
Primary antibiotic resistance in Helicobacter pylori strains isolated in Northern and Central Italy. 159
Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management 158
The Bidirectional Link between Nutritional Factors and Inflammatory Bowel Diseases: Dietary Deficits, Habits, and Recommended Interventions-A Narrative Review 158
Updating Primary Antibiotic Resistance in Helicobacter pylori Strains Isolated in Italy 156
Culture-based antibiotic susceptibility testing for Helicobacter pylori infection: a systematic review 156
high Prevalence of Primary Antibiotic Resistance in Helicobacter pylori Isolates in Italy 154
Effectiveness of first and second-line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management. 150
Diagnosi dell'infezione da Helicobacter pylori 147
A combination of faecal tests for the detection of colon cancer: a new strategy for appropriate selection of referrals to colonoscopy ? A prospective multicenter italian study. 146
Probiotici ricombinanti e loro potenziale sulla salute umana 144
Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management 143
Le molecole strutturali batteriche come potenziali candidate per l’evoluzione del concetto classico di probiotici. 141
Recombinant probiotics and their potential in human health 139
Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains 137
Role of MIC levels of resistance to clarithromycin and metronidazole in Helicobacter pylori eradication 137
Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg) 136
Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013–2022: Data from the European Registry on H. pylori Management (Hp-EuReg) 136
Levofloxacin resistance and multi-drug resistant strains are prevalent in Italy. 133
Efficacy of a new nutraceutical formulation: L-tryptophan, probiotics, charcoal, chamomile, mint, and licorice (COLONIR®) in the improvement of gastrointestinal symptoms in subjects with irritable bowel syndrome 131
High eradication rate with sequential therapy in naïve Helicobacter pylori patients with multi-resistant strains 129
Gluten-Free Diet and Other Celiac Disease Therapies: Current Understanding and Emerging Strategies 128
Efficacy of a New Nutraceutical Formulation in Patients with Symptomatic Uncomplicated Diverticular Disease (SUDD): a Prospective Observational Study 127
Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT 125
Trends in Primary Antibiotic Resistance in H. pylori Strains Isolated in Italy between 2009 and 2019 123
Rescue therapies for H. pylori infection in foreign patients treated in Italy. 122
Next Generation Sequencing for the Prediction of the Antibiotic Resistance in Helicobacter pylori: A Literature Review 121
Comparison of the management of Helicobacter pylori infection between the older and younger European populations 120
Morfologia e modalità di adesione all’epitelio dell’ileo terminale dei batteri filamentosi segmentati. Effetti sulla relazione con il sistema immunitario 120
Pylera and sequential therapy for first-line Helicobacter pylori eradication: A culture-based study in real clinical practice 115
Helicobacter pylori Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on Helicobacter pylori Management 113
More Than 90% Eradication Rate With Sequential Therapy in Clarithromycin Resistant Helicobacter pylori Patients: A Prospective Uncontrolled Study 111
Effectiveness of high-dose esomeprazole or pantoprazole 10-day sequential therapy empirically prescribed in Helicobacter pylori-infected naïve patients: a retrospective study 110
Upper Endoscopy in Patients with Extra-Oesophageal Reflux Symptoms: A Multicentre Study 105
Very-Low-Absorbable Geraniol for the Treatment of Irritable Bowel Syndrome: A "Real-World" Open-Label Study on 1585 Patients. 105
Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection 101
Antibiotic resistance prevalence and trends in patients infected with helicobacter pylori in the period 2013–2020: Results of the european registry on h. pylori management (hp-eureg) 101
Efficacy of a new nutraceutical formulation (CHETOGERD®) in patients with nonerosive reflux (NERD): a prospective observational study. 100
Clinical Performance of the Automated LIAISON® Meridian H. pylori SA Stool Antigen Test 95
Statin therapy may protect against acute kidney injury in patients hospitalized for interstitial SARS-CoV2 pneumonia. 94
Helicobacter pylori eradication following first-line treatment failure in Europe: What, how and when chose among different standard regimens? A systematic review 94
Rescue Therapies for H. pylori Infection in Italy 85
Rescue Therapies for Helicobacter pylori Infection in Foreign Patients Treated in Italy 83
null 81
Clinical Performance of the Automated LIAISON® Meridian H. pylori SA Stool Antigen Test 78
First-line therapies for H. pylori infection in Italy: a pooled-data analysis 74
Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains 73
Culture-based antibiotic susceptibility testing for Helicobacter pylori infection: a systematic review 69
First-line therapies for H. pylori infection in Italy: a pooled-data analysis 62
null 62
A new non-invasive tool for guiding H. pylori treatment. 52
Antibiotic resistance and therapy for H. Pylori infection in immigrant patients treated in Italy 30
Totale 10.413
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.286
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.286
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021186 0 0 0 0 0 0 0 0 0 0 0 186
2021/2022861 78 27 42 84 85 27 28 68 34 35 237 116
2022/20231.073 87 121 69 119 63 82 44 79 234 52 67 56
2023/2024628 29 102 43 76 35 99 32 40 19 52 60 41
2024/20251.980 97 243 155 137 280 124 152 91 64 105 150 382
2025/20264.309 359 449 367 363 387 268 458 157 760 360 239 142
Totale 10.413